Developing Allosteric Chaperones for GBA1-Associated Disorders—An Integrated Computational and Experimental Approach
Authors:
- Marta MontpeyoMMMarta Montpeyo
- Natàlia Pérez-CarmonaNPNatàlia Pérez-Carmona
- Elena CuberoECElena Cubero
- Aida DelgadoADAida Delgado
- Ana RuanoARAna Ruano
- Jokin CarrilloJCJokin Carrillo
- Manolo BellottoMBManolo Bellotto
- Marta Martinez-VicenteMarta Martinez-Vicente
- Ana Maria Garcia-CollazoAGAna Maria Garcia-Collazo
Open Access
- 24 December 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 9
Abstract
Mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are associated with Gaucher disease and increased risk of Parkinson’s disease. This study describes the discovery and characterization of novel allosteric pharmacological chaperones for GCase through an innovative computational approach combined with experimental validation. Utilizing virtual screening and structure-activity relationship optimization, researchers identified several compounds that significantly enhance GCase activity and stability across various cellular models, including patient-derived fibroblasts and neuronal cells harboring GBA1 mutations. Among these, compound 3 emerged as a lead candidate, demonstrating the ability to enhance GCase protein levels and enzymatic activity while effectively reducing the accumulation of toxic substrates in neuronal models. Importantly, pharmacokinetic studies revealed that compound 3 has favorable brain penetration, indicating its potential as a disease-modifying therapy for GBA1-related disorders affecting the central nervous system. This research not only offers a framework for developing allosteric GCase modulators but also unveils promising new therapeutic strategies for managing Gaucher disease and Parkinson’s disease. The ability of compound 3 to cross the blood-brain barrier emphasizes its potential significance in addressing neurological symptoms associated with these conditions.Keywords
Funding Information
- Michael J. Fox Foundation (MJFF 16182, 113321/21/Q, PI20/00728, FPU18/05595)
- Eurostars-2 joint program (MJFF 16182, 113321/21/Q, PI20/00728, FPU18/05595)
- Eureka|Eurostars (MJFF 16182, 113321/21/Q, PI20/00728, FPU18/05595)
- Instituto de Salud Carlos III, EU/Spain (MJFF 16182, 113321/21/Q, PI20/00728, FPU18/05595)
- MINECO (Spain) (MJFF 16182, 113321/21/Q, PI20/00728, FPU18/05595)
This publication has 39 references indexed in Scilit:
- Evaluation of a Liquid Chromatography–Tandem Mass Spectrometry Method for the Analysis of Glucosylceramide and Galactosylceramide Isoforms in Cerebrospinal Fluid of Parkinson’s Disease PatientsAnalytical Chemistry, 2024
- Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicineMovement Disorders, 2018
- N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's diseaseMovement Disorders, 2017
- Glucosylsphingosine is a key biomarker of Gaucher diseaseAmerican Journal of Hematology, 2016
- Enzyme replacement and substrate reduction therapy for Gaucher diseaseCochrane Database of Systematic Reviews, 2015
- Molecular Simulations with Solvent Competition Quantify Water Displaceability and Provide Accurate Interaction Maps of Protein Binding SitesJournal of Medicinal Chemistry, 2014
- Binding Site Detection and Druggability Index from First PrinciplesJournal of Medicinal Chemistry, 2009
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Molecular identification of an N-type Ca2+ channel in saccular hair cellsNeuroscience, 2006